Background Prostate cancer is a heterogeneous disease, but current treatments are not based
on molecular stratification. We hypothesized that metastatic, castration-resistant prostate …

Background Long-term hormone therapy has been the standard of care for advanced prostate
cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, …

Background Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus
prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the …

Background Abiraterone acetate plus prednisolone improves survival in men with relapsed
prostate cancer. We assessed the effect of this combination in men starting long-term …

Background In the interim analyses of the LATITUDE study, the addition of abiraterone acetate
plus prednisone to androgen deprivation therapy (ADT) led to a significant improvement …

Research conducted over the past two decades has shown the importance of the type 1
insulin-like growth factor receptor (IGF1R) in tumorigenesis, metastasis, and resistance to …

Background Non-clear cell renal cell carcinomas are histologically and genetically diverse
kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We …

Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in
a proportion of metastatic urothelial cancers 1 , 2 . Biomarkers may facilitate identification of …

… Warde, Siamak Daneshmand, Andrew Protheroe, Scott Tyldesley, Peter C. Black, Kim Chi,
Alan I. So, Malcom J. … Warde, Siamak Daneshmand, Andrew Protheroe, Scott Tyldesley …

Background Adding abiraterone acetate with prednisolone (AAP) or docetaxel with
prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for …